Whole‐body MRI for staging prostate cancer: a narrative review
BJU International · 2025
DOI: 10.1111/bju.16514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJU International, 2025. Verfasst von Andrew M Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms, Whole Body Imaging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Objective
To present a narrative review regarding the diagnostic accuracy of whole‐body magnetic resonance imaging (WBMRI) in staging patients with high‐risk prostate cancer (HRPCa) and compare it to established imaging modalities.
Methods
A narrative review was carried out using PubMed using the following keywords: ‘whole body’, ‘magnetic resonance imaging’, ‘MRI’, ‘prostate cancer’, ‘risk stratification’, and ‘staging’. Articles that evaluated WBMRI as the imaging modality to stage patients with HRPCa were included, while studies that solely assessed for biochemical recurrence or metastatic disease progression were excluded.
Results
In the evaluation of lymphatic metastases, WBMRI has demonstrated a comparable, if not improved, sensitivity and specificity compared to conventional imaging of computed tomography (CT). Furthermore, WBMRI demonstrates improved sensitivity and specificity in detecting bone metastases compared to bone scintigraphy (BS). However, with advent of prostate‐specific membrane antigen (PSMA) radioligands for positron emission tomography (PET), the diagnostic performance of WBMRI to detect metastatic disease appears inferior.
Conclusions
The diagnostic capabilities of WBMRI exceed that of conventional imaging of CT and BS in detecting metastatic disease in patients with HRPCa. However, WBMRI does not perform as well as PSMA PET/CT. Further study on cost comparisons between WBMRI and PSMA PET/CT are needed, as well as evaluations of combined PSMA PET/MRI are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Andrew M Fang, Justin R Gregg
Zitieren
APA
Fang, A. M., Gregg, J. R., Pettaway, C., Ma, J., Szklaruk, J., Bathala, T. K., Surasi, D. S. S., & Chapin, B. F. (2025). Whole‐body MRI for staging prostate cancer: a narrative review. BJU International. https://doi.org/10.1111/bju.16514
Vancouver
Fang AM, Gregg JR, Pettaway C, Ma J, Szklaruk J, Bathala TK, et al. Whole‐body MRI for staging prostate cancer: a narrative review. BJU International. 2025. doi:10.1111/bju.16514
BibTeX
@article{Fang2025,
author = {Fang, Andrew M and Gregg, Justin R and Pettaway, Curtis and Ma, Jingfei and Szklaruk, Janio and Bathala, Tharakeswara K and Surasi, Devaki Shilpa S and Chapin, Brian F},
title = {Whole‐body MRI for staging prostate cancer: a narrative review},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16514}
}
EUVIMED